LW

Leyi Wang

Partner at 6 Dimensions Capital

Boston, Massachusetts

Overview 

Leyi Wang is currently a Partner and Managing Director at 6 Dimensions Capital, with a background in Life Science Venture Investing. With previous roles at Phoenix Tissue Repair, Inc. as Vice President of Business Development and Operations, as well as experience at BridgeBio as Director of Portfolio Intelligence, Leyi has demonstrated expertise in strategic planning and business development within the pharmaceutical and biotechnology industries.

Work Experience 

6D

6 Dimensions Capital

  • Partner

    2022 - Current

  • Managing Director

    2019 - 2021

    http://www.6dimensionscapital.com/en/home/

Phoenix Tissue Repair, Inc.

  • Vice President of Business Development and Operations

    2018 - 2019

B

BridgeBio

  • Director, Portfolio Intelligence

    2018 - 2019

BridgeBio focuses on the development and commercialization of precision medicines for various genetic diseases and cancers.

Raised $3,849,200,000.00 from Blue Owl and CPP Investments.

bridgebio.com

WuXi NextCODE

  • Director of Corporate Development

    2017 - 2018

Leerink Partners LLC

  • Vice President, Equity Research

    2017 - 2017

  • Associate, Equity Research

    2015 - 2017

    Large Cap Pharmaceutical/SMID-cap Biotechnology Equity Research Large-cap U.S. and EU pharmaceutical companies and select SMID-cap biotech/spec pharma in the oncology, diabetes and dermatology space

LC

L.E.K. Consulting

  • Life Sciences Specialist / Senior Life Sciences Specialist / Strategy Consulting

    2013 - 2015

    As a Life Science Specialist/Senior Life Science Specialist at L.E.K. Consulting, I worked on projects for pharmaceutical, biotech, and diagnostic companies across functional areas, including portfolio prioritization, R&D planning, new product launch strategy, and M&A transaction due diligence. Select client engagements include: • Global revenue forecast for an orphan pipeline drug for a small biotech company • Investment strategy assessment and validation for a new biopharma-focused investment fund • Company valuation and market assessment for a biotech company focused on biosimilars • Market research on a new hematology product and prepare launch plan for senior management

WC

Weill Cornell Medical College

  • PhD student

    2007 - 2013

    PhD in Biophysics; single-molecule fluorescence resonance energy transfer (smFRET) imaging of ribosome

Weill Cornell Medicine is an academic medical institution that offers health care services.

Raised $53,500,000.00 from National Cancer Institute, National Institutes of Health, UnitedHealthcare and National Institutes of Health.

weill.cornell.edu

Education 

Articles About Leyi

Relevant Websites